Evidence map›Paper›PMID 36223927›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.

Aki Murayama, Keizo Sugaya, Makoto Hara, Tomoya Kawazoe, Shinsuke Tobisawa, Hideto Nakajima, Kazushi Takahashi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aki MurayamaDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.
Keizo SugayaDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.
Makoto HaraDivision of Neurology, Department of Medicine, Nihon University School of Medicine, Japan.
Tomoya KawazoeDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.
Shinsuke TobisawaDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.
Hideto NakajimaDivision of Neurology, Department of Medicine, Nihon University School of Medicine, Japan.
Kazushi TakahashiDepartment of Neurology, Tokyo Metropolitan Neurological Hospital, Japan.
Tokyo Metropolitan Neurological Hospital · JPNihon University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coexistence of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) autoantibodies in the same individual is surprisingly often observed. We herein report the first case of LGI1 encephalitis followed by Isaacs syndrome in which LGI1 and CASPR2 antibodies in the serum and cerebrospinal fluid (CSF) were measured during the entire disease course. After the resolution of limbic encephalitis, LGI1 antibodies disappeared from the CSF simultaneously with the appearance of CASPR2 antibodies in the serum. The alternating presence of these pathogenic autoantibodies along with the clinical and phenotypic alternations suggested that LGI1 encephalitis was associated with CASPR2 autoantibody production in the peripheral tissue, leading to CASPR2-associated Isaacs syndrome.

Indexed as

EncephalitisIsaacs SyndromeLimbic EncephalitisAutoantibodiesContactinsHumansIntracellular Signaling Peptides and ProteinsLeucineAutoantibodiesContactinsIntracellular Signaling Peptides and ProteinsLeucineautoantibodiescontactin-associated protein-like 2 (CASPR2)Isaacs syndromeleucine-rich glioma-inactivated 1 (LGI1)limbic encephalitis

Identifiers

PMID36223927
PMCPMC10292997
OpenAlexW4304593284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.